BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37589430)

  • 21. High expression of Chitinase 3-like-1 is an unfavorable prognostic factor in urothelial carcinoma of upper urinary tract and urinary bladder.
    Lee YE; Chan TC; Tian YF; Liang PI; Shiue YL; Chen YS; He HL
    Urol Oncol; 2019 May; 37(5):299.e7-299.e18. PubMed ID: 30660494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.
    Miyata Y; Matsuo T; Nakamura Y; Yasuda T; Ohba K; Takehara K; Sakai H
    Anticancer Res; 2018 Mar; 38(3):1629-1635. PubMed ID: 29491095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytokeratin 20 immunocytochemistry on urine sediments: A potential low-cost adjunct to cytology in the diagnosis of low-grade urothelial carcinoma.
    Wadhwa N; Diwaker P; Lotha N; Arora VK; Singh N
    Cytopathology; 2017 Dec; 28(6):531-535. PubMed ID: 28940433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p16/Ki-67 dual labeling and urinary cytology results according to the New Paris System for Reporting Urinary Cytology: Impact of extended follow-up.
    Piaton E; Advenier AS; Carré C; Decaussin-Petrucci M; Mège-Lechevallier F; Hutin K; Nennig C; Colombel M; Ruffion A
    Cancer Cytopathol; 2017 Jul; 125(7):552-562. PubMed ID: 28371465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significance of p53, p27, Ki-67, E-cadherin, and HER2 expression in upper urinary tract urothelial carcinoma.
    Missaoui N; Bdioui A; Baccouche A; Belkacem O; Hmida W; Mokni M; Hmissa S
    J Egypt Natl Canc Inst; 2020 Sep; 32(1):36. PubMed ID: 32929553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of atypical urine cytology progression to malignancy.
    Muus Ubago J; Mehta V; Wojcik EM; Barkan GA
    Cancer Cytopathol; 2013 Jul; 121(7):387-91. PubMed ID: 23536358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of urine cytology and fluorescence in situ hybridization in upper urothelial tract samples.
    Reynolds JP; Voss JS; Kipp BR; Karnes RJ; Nassar A; Clayton AC; Henry MR; Sebo TJ; Zhang J; Halling KC
    Cancer Cytopathol; 2014 Jun; 122(6):459-67. PubMed ID: 24604675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Upregulation of dihydropyrimidinase-like 3 (DPYSL3) protein predicts poor prognosis in urothelial carcinoma.
    Liang PI; Lai HY; Chan TC; Li WM; Hsing CH; Huang SK; Hsieh KL; Tseng WH; Chen TJ; Li WS; Chen HD; Kuo YH; Li CF
    BMC Cancer; 2023 Jun; 23(1):599. PubMed ID: 37380971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positive voided urine cytology predicts worse pathological findings of nephroureterectomy specimens in patients with upper tract urothelial carcinoma: does selective ureteral cytology have an additional efficacy?
    Sakano S; Inamoto T; Inoue R; Matsumoto H; Nagao K; Yamamoto Y; Azuma H; Matsuyama H
    Jpn J Clin Oncol; 2015 Oct; 45(10):968-72. PubMed ID: 26232447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Tumor cell-based glycolytic metabolism and single-cell sequencing of urinary exfoliated cells for the diagnosis and molecular profiling of urothelial carcinoma].
    Xiao XY; Zhao H; Guo HQ; Wang C; Sun Y; Chang XX; Zhao LL; Zhang ZH
    Zhonghua Bing Li Xue Za Zhi; 2023 May; 52(5):472-479. PubMed ID: 37106289
    [No Abstract]   [Full Text] [Related]  

  • 31. Consultation on UTUC, Stockholm 2018 aspects of diagnosis of upper tract urothelial carcinoma.
    Fojecki G; Magnusson A; Traxer O; Baard J; Osther PJS; Jaremko G; Seitz C; Knoll T; Giusti G; Brehmer M
    World J Urol; 2019 Nov; 37(11):2271-2278. PubMed ID: 30915526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of β-tubulin isotypes in urothelial carcinoma of the bladder.
    Choi JW; Kim Y; Lee JH; Kim YS
    World J Urol; 2014 Apr; 32(2):347-52. PubMed ID: 23184177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. βIII-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma.
    Quaas A; Rahvar AH; Burdelski C; Koop C; Eichelberg C; Rink M; Dahlem R; Schlomm T; Tsourlakis MC; Simon R; Minner S; Sauter G; Steurer S
    World J Urol; 2015 Oct; 33(10):1561-9. PubMed ID: 25527909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Keratin 17 Is a Novel Cytologic Biomarker for Urothelial Carcinoma Diagnosis.
    Babu S; Kim NW; Wu M; Chan I; Escobar-Hoyos LF; Shroyer KR
    Am J Clin Pathol; 2021 Oct; 156(5):926-933. PubMed ID: 34086841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological characteristics and outcomes of synchronous renal cell carcinoma and urothelial carcinoma: A population-based analysis.
    Wu K; Liu X; Wang Y; Wang X; Li X
    Front Public Health; 2022; 10():994351. PubMed ID: 36388369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluorodeoxyglucose positron emission tomography/computed tomography for diagnosis of upper urinary tract urothelial carcinoma.
    Asai S; Fukumoto T; Tanji N; Miura N; Miyagawa M; Nishimura K; Yanagihara Y; Shirato A; Miyauchi Y; Kikugawa T; Yokoyama M
    Int J Clin Oncol; 2015 Oct; 20(5):1042-7. PubMed ID: 25794920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-level Ki-67 expression as an independent predictor of bladder tumour recurrence in patients with primary upper tract urothelial carcinoma after radical nephroureterectomy.
    Wu P; Liu S; Zhang W; Zhang Y; Zhu G; Wei D; Wan B; Wang J
    Jpn J Clin Oncol; 2015 Dec; 45(12):1175-81. PubMed ID: 26450700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Value of p16(INK4a) in the diagnosis of low-grade urothelial carcinoma of the urinary bladder in urinary cytology.
    Alameda F; Juanpere N; Pijuan L; Lloveras B; Gimeno J; Baró T; Salido M; Serrano S; Lloreta J
    Cancer Cytopathol; 2012 Aug; 120(4):276-82. PubMed ID: 22419364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urine cytology findings in patients with biopsy-confirmed urothelial carcinoma in situ with plasmacytoid features.
    Nichols MM; Reynolds JP; McKenney JK; Nicolas MM; McIntire PJ; Policarpio-Nicolas MLC
    Cancer Cytopathol; 2021 Oct; 129(10):798-804. PubMed ID: 33900681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Molecular Diagnostics of the Involvement of Visually Normal Mucosa in the Malignancy Process in Urothelial Bladder Cancer].
    Bogush TA; Basharina AA; Safarov ZM; Mizaeva IE; Grishanina AN; Bogush EA; Gridneva YV; Volkova MI; Matveev VB; Kosorukov VS
    Mol Biol (Mosk); 2022; 56(4):642-651. PubMed ID: 35964320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.